ARTICLE | Management Tracks
Slaoui stepping back from all biopharma roles, expresses ‘deep regrets’ following sexual harassment claim
March 25, 2021 2:14 AM UTC
Former Operation Warp Speed leader Moncef Slaoui implied that he is taking a leave of absence from all his professional roles following his termination as Galvani’s chairman by GSK due to sexual harassment allegations.
Slaoui, a 30-year veteran of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) who served as head of vaccines R&D for eight years, is a partner at Medicxi and chairman of Medicxi portfolio companies Divide & Conquer and Vaxcyte Inc. (NASDAQ:PCVX). He’s also CSO of newly launched Medicxi portfolio company Centessa Pharmaceuticals Ltd., and a member of BIO’s Health & Regulatory Affairs Committee. Slaoui concluded his work as scientific adviser and co-leader of Operation Warp Speed at the end of 2020...